DK1698640T4 - Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. - Google Patents

Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. Download PDF

Info

Publication number: DK1698640T4
Authority: DK; Denmark
Prior art keywords: antibody; procedure; stabilizing; stabilized solution; preparation
Prior art date: 2003-10-01

Application number

DK04773700.2T

Other languages

English (en)

Other versions

DK1698640T3 (da

Inventor

Yuji C/O Kyowa Hakko Kogyo Co Ltd Ueno

Takashi C/O Kyowa Hakko Kogyo Co Ltd Kayashita

Atsushi C/O Kyowa Hakko Kogyo Co Ltd Ishihara

Masashi C/O Kyowa Hakko Kogyo Co Ltd Nakakura

Kyoko C/O Kyowa Hakko Kogyo Co Ltd Yamauchi

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-01

Filing date

2004-10-01

Publication date

2019-09-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34419308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1698640(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-01 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2016-02-15 Application granted granted Critical

2016-02-15 Publication of DK1698640T3 publication Critical patent/DK1698640T3/da

2019-09-02 Publication of DK1698640T4 publication Critical patent/DK1698640T4/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK04773700.2T 2003-10-01 2004-10-01 Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. DK1698640T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003343645		2003-10-01
PCT/JP2004/014903 WO2005033143A1 (ja)	2003-10-01	2004-10-01	抗体の安定化方法及び安定化された溶液状抗体製剤

Publications (2)

Publication Number	Publication Date
DK1698640T3 DK1698640T3 (da)	2016-02-15
DK1698640T4 true DK1698640T4 (da)	2019-09-02

Family

ID=34419308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04773700.2T DK1698640T4 (da)	2003-10-01	2004-10-01	Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.

Country Status (15)

Country	Link
US (3)	US8496930B2 (da)
EP (2)	EP3006463A1 (da)
JP (1)	JP4219932B2 (da)
KR (1)	KR100911091B1 (da)
CN (1)	CN100522998C (da)
AU (1)	AU2004277466C1 (da)
CA (1)	CA2540848C (da)
CY (1)	CY1117215T1 (da)
DK (1)	DK1698640T4 (da)
ES (1)	ES2562912T5 (da)
HU (1)	HUE026793T2 (da)
PL (1)	PL1698640T5 (da)
PT (1)	PT1698640E (da)
SI (1)	SI1698640T2 (da)
WO (1)	WO2005033143A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7883704B2 (en) *	1999-03-25	2011-02-08	Abbott Gmbh & Co. Kg	Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
WO2005033143A1 (ja)	2003-10-01	2005-04-14	Kyowa Hakko Kogyo Co., Ltd.	抗体の安定化方法及び安定化された溶液状抗体製剤
WO2006125207A2 (en) *	2005-05-19	2006-11-23	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
MX2008001068A (es) *	2005-07-29	2008-03-19	Amgen Inc	Formulacion que inhibe la agregacion de proteina.
BRPI0710826A2 (pt)	2006-04-21	2011-08-23	Novartis Ag	composições farmacêuticas de anticorpo anti-cd40 antagonista
AU2007234612B2 (en)	2006-12-14	2013-06-27	Johnson & Johnson Regenerative Therapeutics, Llc	Protein stabilization formulations
CA2675233A1 (en) *	2007-01-16	2008-07-24	Abbott Laboratories	Methods for treating psoriasis
AU2008233173B2 (en)	2007-03-29	2013-09-19	Abbvie Inc.	Crystalline anti-human IL-12 antibodies
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
TWI543768B (zh) *	2007-11-30	2016-08-01	艾伯維生物技術有限責任公司	蛋白質調配物及製造其之方法
TWI461210B (zh) *	2008-03-18	2014-11-21	Abbvie Inc	治療牛皮癬的方法
US8557239B2 (en) *	2009-09-14	2013-10-15	Abbvie Inc.	Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
EP2350649A4 (en) *	2008-11-28	2012-11-14	Abbott Lab	STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
WO2010129469A1 (en) *	2009-05-04	2010-11-11	Abbott Biotechnology Ltd.	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
AU2010255748B2 (en) *	2009-06-04	2014-03-13	Alk-Abello A/S	Stabilised composition comprising at least one adrenergic compound
EP2538973A2 (en)	2010-02-26	2013-01-02	Novo Nordisk A/S	Stable antibody containing compositions
AU2011223710B2 (en)	2010-03-01	2016-04-14	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US20130136733A1 (en)	2010-05-28	2013-05-30	Novo Nordisk A/S	Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
CN103282042B (zh) *	2010-09-17	2014-12-10	巴克斯特国际公司	通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白
JP5919606B2 (ja)	2010-11-11	2016-05-18	アッヴィバイオテクノロジーリミテッド	改良型高濃度抗ｔｎｆアルファ抗体液体製剤
US9969794B2 (en)	2012-05-10	2018-05-15	Visterra, Inc.	HA binding agents
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
WO2014115882A1 (ja)	2013-01-28	2014-07-31	国立大学法人熊本大学	タンパク質を安定化させたゲル状製剤
BR112016000563A2 (pt) *	2013-07-19	2017-09-05	Hexal Ag	Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica
CN103772505B (zh) *	2013-12-18	2014-10-15	长春博迅生物技术有限责任公司	一种抗体试剂保存液
WO2017083627A1 (en)	2015-11-13	2017-05-18	Visterra, Inc.	Compositions and methods for treating and preventing influenza
CN109195629A (zh) *	2016-02-24	2019-01-11	威特拉公司	流行性感冒抗体分子制剂
WO2017170626A1 (ja) *	2016-03-30	2017-10-05	千寿製薬株式会社	水性液剤
KR102735988B1 (ko)	2019-02-18	2024-12-03	일라이 릴리 앤드 캄파니	치료 항체 제제
CA3132521A1 (en)	2019-03-25	2020-10-01	Visterra, Inc.	Compositions and methods for treating and preventing influenza
WO2021070203A1 (en) *	2019-10-11	2021-04-15	Dr. Reddy's Laboratories Limited	Stable formulation of integrin antibody
AU2022270665A1 (en) *	2021-05-05	2023-12-07	I2O Therapeutics, Inc.	Ionic liquid formulations for treating inflammatory and autoimmune diseases
IL312672A (en)	2021-11-10	2024-07-01	I2O Therapeutics Inc	Ionic liquid compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US421777A (en) *		1890-02-18		Straining-pot
JPH0669961B2 (ja)	1984-09-25	1994-09-07	株式会社ミドリ十字	免疫グロブリンの加熱処理方法
US4597966A (en)	1985-01-09	1986-07-01	Ortho Diagnostic Systems, Inc.	Histidine stabilized immunoglobulin and method of preparation
JPS62194459A (ja) *	1986-02-21	1987-08-26	Sankyo Co Ltd	固相化試薬の安定化剤
JPS62244441A (ja)	1986-04-16	1987-10-24	Green Cross Corp:The	抗体固定化担体
DE3734923C1 (de) *	1987-10-15	1989-01-26	Biotest Pharma Gmbh	Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
WO1989011298A1 (en)	1988-05-27	1989-11-30	Centocor, Inc.	Formulation for antibody reagents
US5945098A (en) *	1990-02-01	1999-08-31	Baxter International Inc.	Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) *	1991-03-08	1993-03-19	Mitsui Toatsu Chem Inc	モノクローナル抗体含有凍結乾燥製剤
JP2966592B2 (ja) *	1991-07-20	1999-10-25	萩原義秀	安定化されたヒトモノクローナル抗体製剤
CA2078539C (en)	1991-09-18	2005-08-02	Kenya Shitara	Process for producing humanized chimera antibody
GB9122820D0 (en)	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
ES2124308T3 (es) *	1992-04-30	1999-02-01	Cor Therapeutics Inc	Composicion estable de polipeptidos.
JPH06189781A (ja) *	1992-12-25	1994-07-12	Mitsui Toatsu Chem Inc	培養液中の生理活性タンパク質の安定化方法
FR2708467B1 (fr) *	1993-07-30	1995-10-20	Pasteur Merieux Serums Vacc	Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
GB9418092D0 (en)	1994-09-08	1994-10-26	Red Cross Found Cent Lab Blood	Organic compounds
MX9706827A (es)	1995-03-10	1997-11-29	Genentech Inc	Activacion de receptor por gas6.
WO1999037329A1 (en) *	1998-01-22	1999-07-29	Astrazeneca Ab	Pharmaceutical formulation comprising an antibody and a citrate buffer
US6488930B1 (en) *	1999-01-15	2002-12-03	Millennium Pharmaceuticals, Inc.	Anti-CCR4 antibodies and methods of use therefor
WO2000066160A1 (fr)	1999-04-28	2000-11-09	Yamanouchi Pharmaceutical Co., Ltd.	Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
EP1050307A1 (en)	1999-05-06	2000-11-08	Applied Research Systems ARS Holding N.V.	CCR4 antagonists in sepsis
CN100381172C (zh)	1999-06-25	2008-04-16	吉尼泰克公司	使用抗-ErbB2抗体治疗前列腺癌
AU784187B2 (en)	1999-09-30	2006-02-16	Kyowa Hakko Kogyo Co. Ltd.	Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3
WO2001047554A1 (fr)	1999-12-28	2001-07-05	Chugai Seiyaku Kabushiki Kaisha	Compositions d'anticorps stables et preparations pour injection
US6989145B2 (en)	2000-03-03	2006-01-24	Kyowa Hakko Kogyo Co., Ltd.	Recombinant antibody and antibody fragment
EP2311492B1 (en)	2000-08-11	2017-10-04	Chugai Seiyaku Kabushiki Kaisha	Antibody-containing stabilized preparations
CN100430420C (zh)	2001-08-31	2008-11-05	协和发酵工业株式会社	人cdr-移植抗体及其抗体片段
MXPA04004224A (es)	2001-11-02	2005-03-31	Johnson & Johnson	Proteinas del virus sincitial respiratorio, anticuerpos, composiciones, metodos y usos.
DE60334678D1 (de)	2002-02-14	2010-12-09	Chugai Pharmaceutical Co Ltd	Antikörper enthaltende pharmazeutische lösungen
WO2005033143A1 (ja) *	2003-10-01	2005-04-14	Kyowa Hakko Kogyo Co., Ltd.	抗体の安定化方法及び安定化された溶液状抗体製剤

2004
- 2004-10-01 WO PCT/JP2004/014903 patent/WO2005033143A1/ja not_active Ceased
- 2004-10-01 EP EP15191413.2A patent/EP3006463A1/en active Pending
- 2004-10-01 ES ES04773700T patent/ES2562912T5/es not_active Expired - Lifetime
- 2004-10-01 SI SI200432297T patent/SI1698640T2/sl unknown
- 2004-10-01 HU HUE04773700A patent/HUE026793T2/en unknown
- 2004-10-01 DK DK04773700.2T patent/DK1698640T4/da active
- 2004-10-01 JP JP2005514512A patent/JP4219932B2/ja not_active Expired - Lifetime
- 2004-10-01 AU AU2004277466A patent/AU2004277466C1/en active Active
- 2004-10-01 PT PT47737002T patent/PT1698640E/pt unknown
- 2004-10-01 CN CNB2004800271879A patent/CN100522998C/zh not_active Expired - Lifetime
- 2004-10-01 PL PL04773700T patent/PL1698640T5/pl unknown
- 2004-10-01 US US10/574,016 patent/US8496930B2/en active Active
- 2004-10-01 EP EP04773700.2A patent/EP1698640B2/en not_active Expired - Lifetime
- 2004-10-01 CA CA2540848A patent/CA2540848C/en not_active Expired - Lifetime
2006
- 2006-03-31 KR KR1020067006311A patent/KR100911091B1/ko not_active Expired - Lifetime
2013
- 2013-06-14 US US13/918,507 patent/US9011850B2/en not_active Expired - Lifetime
2015
- 2015-03-18 US US14/661,510 patent/US10172790B2/en active Active
2016
- 2016-02-23 CY CY20161100147T patent/CY1117215T1/el unknown

Also Published As

Publication number	Publication date
US8496930B2 (en)	2013-07-30
US10172790B2 (en)	2019-01-08
CY1117215T1 (el)	2017-04-05
PT1698640E (pt)	2016-03-31
AU2004277466B2 (en)	2010-04-01
AU2004277466C1 (en)	2022-06-23
EP1698640A4 (en)	2008-09-17
CA2540848C (en)	2012-12-11
US20130280248A1 (en)	2013-10-24
PL1698640T3 (pl)	2016-05-31
EP3006463A1 (en)	2016-04-13
CN1856507A (zh)	2006-11-01
US20070020255A1 (en)	2007-01-25
ES2562912T3 (es)	2016-03-09
AU2004277466A1 (en)	2005-04-14
HUE026793T2 (en)	2016-07-28
JP4219932B2 (ja)	2009-02-04
SI1698640T1 (sl)	2016-03-31
DK1698640T3 (da)	2016-02-15
JPWO2005033143A1 (ja)	2007-11-15
EP1698640A1 (en)	2006-09-06
EP1698640B1 (en)	2015-12-30
CA2540848A1 (en)	2005-04-14
KR20060089227A (ko)	2006-08-08
SI1698640T2 (sl)	2019-08-30
CN100522998C (zh)	2009-08-05
ES2562912T5 (es)	2020-02-18
EP1698640B2 (en)	2019-06-19
US20150190507A1 (en)	2015-07-09
HK1090933A1 (en)	2007-01-05
US9011850B2 (en)	2015-04-21
PL1698640T5 (pl)	2019-12-31
KR100911091B1 (ko)	2009-08-06
WO2005033143A1 (ja)	2005-04-14

Publication	Publication Date	Title
DK1698640T4 (da)	2019-09-02	Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.
DK1575416T3 (da)	2014-01-13	Fremgangsmåder til diagnosticering af præeklampsi
DK1504126T3 (da)	2014-06-10	Fremgangsmåde til regulering af genekspression
DK1599478T3 (da)	2007-09-17	Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DK1427730T3 (da)	2006-11-06	Nye dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DK1748077T3 (da)	2013-04-08	Fremgangsmåde til fremstilling af protein
DK2929891T3 (da)	2020-05-11	Fremgangsmåde til modulering af appetitten
EP1784219A4 (en)	2010-02-17	STABILIZING FORMULATIONS
IS2935B (is)	2016-01-15	Misnotkunarvarið lyfjaform til skömmtunar um húð
DK1414803T3 (da)	2013-03-25	Pyrazolylcarboxanilider som fungicider
DK1451143T3 (da)	2008-11-10	Fremgangsmåder til fremstilling af O-desmethylvenlafaxin
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK2135957T3 (da)	2019-05-13	Fremgangsmåde til fremstilling af glucaner
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
DK2508521T4 (da)	2022-10-03	Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK1907373T3 (da)	2013-02-04	Fremgangsmåder til fremstillingen af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dionforbindelser
DK1549341T3 (da)	2009-07-06	Mod vævsfaktor rettede antistoffer som antikoagulanter
DK1638928T3 (da)	2011-01-17	N-alkynyl-2-(substituerede aryloxy)alkylthio-amidderivater som fungicider
NL1027608A1 (nl)	2005-05-31	Automatisch uitlijnend scintillator-collimatorsamenstel.
ITRM20050287A1 (it)	2005-12-18	Polsino per orologio.
DK1536685T3 (da)	2006-08-14	Fremgangsmåde til fremstilling af pasta-ekstruderede sulfonamidsammensætninger
DK1611884T3 (da)	2012-12-10	Plaster, indeholdende diclofenac
ITMO20020337A1 (it)	2004-05-22	Dispositivo per anastomosi.
DK1756049T3 (da)	2008-02-25	Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1713801T3 (da)	2008-03-17	Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin